
IGMS Stock Forecast & Price Target
IGMS Analyst Ratings
Bulls say
IGM Biosciences Inc. is positioned favorably due to its novel IgM antibody technology platform, which has shown promise in developing therapeutics for several serious medical conditions, including cancer and autoimmune diseases. The ongoing collaboration with Sanofi (SNY) to develop IgM agonists presents significant revenue potential, with nearly $3 billion in possible milestone earnings pending the successful development of viable candidates. Additionally, the differentiated safety profiles of IgM-based therapeutics may enhance their competitive edge in the expanding autoimmune treatment market, further supporting a positive outlook for the company's stock.
Bears say
IGM Biosciences Inc. faces a negative outlook primarily due to the discontinuation of its key IgM-based bispecific antibody programs, which undermines potential revenue streams and raises concerns about the company's long-term viability. Additionally, the firm's inability to secure external funding, coupled with disappointing efficacy results from current clinical candidates such as Aplitabart and Imvotamab, further exacerbates financial instability. As operational costs continue to rise amid non-revenue-generating status, the likelihood of significant fluctuations in stock price remains high, indicating a precarious position for shareholders.
This aggregate rating is based on analysts' research of IGM Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IGMS Analyst Forecast & Price Prediction
Start investing in IGMS
Order type
Buy in
Order amount
Est. shares
0 shares